# A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

Source: https://onco.cc/trials/nct05583617/  
OnCo record `nct05583617` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cevostamab, Lenalidomide, Tocilizumab in multiple myeloma, run by Hoffmann-La Roche, now recruiting.

## Summary

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma is a phase 1/2 interventional study registered as NCT05583617 by Hoffmann-La Roche, with 200 participants planned, started 2023-11-14 and due to reach its primary completion in 2028-07-31. Interventions recorded: Cevostamab, Lenalidomide, Tocilizumab, Iberdomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05583617
- Phase: 1/2
- Setting: A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma
- Sponsor: Hoffmann-La Roche
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05583617: https://clinicaltrials.gov/study/NCT05583617

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Cevostamab](https://onco.cc/drugs/cevostamab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Iberdomide](https://onco.cc/drugs/iberdomide/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct05583617.json